Key result
Interferon-beta1b significantly reduced total lesion volume by 2% compared to a 15% increase with placebo in patients with secondary progressive multiple sclerosis.
Why the study?
Does interferon-beta1b reduce MRI lesion volume and activity in patients with secondary progressive multiple sclerosis?
RCT (n=718)
double-blind
randomized
Yes
Does interferon-beta1b reduce MRI lesion volume and activity in patients with secondary progressive multiple sclerosis?
Absolute Event Rate: -2% vs 15%
Interferon-beta1b significantly reduces the accumulation of new inflammatory disease foci on MRI in patients with secondary progressive multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Supports interferon-beta1b to limit lesion volume increase in secondary progressive MS; extends disease-modifying effects to progressive forms.
Miller et al. (1999) conducted an RCT in secondary progressive multiple sclerosis (n=718). interferon-beta1b vs. placebo was evaluated on total lesion volume change from baseline to last scan. Interferon-beta1b significantly reduced total lesion volume by 2% compared to a 15% increase with placebo in patients with secondary progressive multiple sclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: